Sponsors (62)
The bill aims to improve diagnosis, treatment, workforce capacity, and equity for people with rare kidney diseases through modest, targeted funding for centers, studies, fellowships, and outreach — but its limited authorizations, potential fiscal trade-offs, implementation gaps, privacy risks around genetic work, and possible administrative burdens mean benefits may be constrained without further investment and safeguards.
People with rare kidney diseases (including those at risk of APOL1-related disease) are likely to get earlier and better diagnosis and treatment options — potentially delaying or avoiding dialysis or transplant — because the bill funds research centers, studies, clinician training, and awareness efforts.
More trained nephrologists and reduced workforce barriers (through fellowships, stipends, and workforce-focused study recommendations) should expand specialist access, especially in underserved and rural communities.
The bill targets racial and ethnic disparities (including APOL1 research and trust-building), which could lead to policies and practices that improve outcomes for impacted minority communities.
The bill increases federal spending (authorizations for centers, studies, fellowships, and pilot work), which raises costs for taxpayers and could crowd out other priorities or require offsets.
The authorized funding levels are modest relative to nationwide needs (e.g., a $6M/year cap for centers and small study budgets), which may limit the number, scale, and geographic reach of funded centers and programs.
Authorizing studies and reports does not change insurance coverage; patients may wait for recommended coverage or system changes, and implementing recommendations could require substantial additional spending by Medicare, Medicaid, and states.
Based on analysis of 5 sections of legislative text.
Authorizes regional NIDDK Centers, HHS studies and ESRD experiments, and nephrology fellowship awards to boost research, testing, training, and public awareness on rare kidney disease.
Official title: To amend the Public Health Service Act with respect to preventing end-stage kidney disease, and for other purposes.
Introduced February 24, 2025 by Gus Bilirakis · Last progress February 24, 2025
Creates and funds regional Centers of Excellence for research, clinical training, outreach, and public awareness about rare kidney diseases and primary glomerular disease, with grants administered by the NIDDK. Requires studies and demonstrations on testing, prevention, genetics (including APOL1), treatment approaches to delay or avoid dialysis/transplant, workforce training in nephrology, and public awareness efforts; provides multi-year grant authority and reporting deadlines to Congress. Authorizes dedicated funding streams for center grants, a federal study on testing/treatment/access under Medicare/Medicaid/private plans, nephrology fellowship awards to expand provider capacity, and Secretary-level experiments and a 24-month report on methods to reduce progression to end-stage kidney disease and increase public awareness.